MIRA Pharma Reports 21-Day Preclinical Proof-Of-Concept Study Showing That Once-Daily Oral MIRA-55 Significantly Reduced Mechanical And Thermal Pain Hypersensitivity; Results Back MIRA-55's Progress Toward IND Filing
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapies for neurologic, inflammatory and metabolic disorders, today
MIRA tested a new pain medicine in animals and got good early results. This is one small step toward proving the drug might work in people.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.